市場調査レポート
商品コード
1064097

がん免疫療法の世界市場:用途別、エンドユーザー別、地域別分析-予測(~2028年)

Cancer Immunotherapy Market Forecasts to 2028 - Global Analysis By Application (Blood Cancers, Ovarian Cancer, Pancreatic Cancer, Liver Cancer), End User (Hospitals & Clinics, Ambulatory Surgical Centres) and By Geography

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
がん免疫療法の世界市場:用途別、エンドユーザー別、地域別分析-予測(~2028年)
出版日: 2022年02月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん免疫療法の市場規模は、2021年に1,193億9,000万米ドルとなり、2028年には3,374億2,000万米ドルに達し、予測期間中のCAGRは16.0%となる見込みです。

当レポートでは、世界のがん免疫療法市場について調査分析し、促進要因、抑制要因、製品・用途・エンドユーザー・地域別市場分析、企業プロファイルを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 市場機会
  • 脅威
  • 製品分析
  • 用途分析
  • エンドユーザー分析
  • 新興市場
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 がん免疫療法の世界市場:製品別

  • サイトカイン・免疫調節剤
    • 顆粒球マクロファージコロニー刺激因子(Gm-Csf&G-Csf)
    • インターロイキン(IL)
    • インターフェロン(IFN)
    • 溶血性ウイルス
  • 養子細胞移植
  • ワクチン
    • 治療用ワクチン
    • 予防用ワクチン
  • モノクローナル抗体
    • 結合型モノクローナル抗体
    • ネイキッドモノクローナル抗体
    • バイスペシフィックモノクローナル抗体
  • 細胞治療
    • 樹状細胞
    • キメラ抗原受容体(CAR)T細胞療法
  • チェックポイント阻害剤
    • Pプログラム死1(PD-1)&プログラム死リガンド1(PD-L1)
    • 細胞障害性Tリンパ球関連タンパク質-4 (CTLA-4)

第6章 がん免疫療法の世界市場:用途別

  • 血液がん
  • 卵巣がん
  • 膵臓がん
  • 肝臓がん
  • 乳がん
  • 黒色腫
  • 肺がん
  • 胃がん
  • 子宮頸がん
  • 前立腺がん
  • 多発性骨髄腫
  • 頭頸部がん
  • 大腸がん
  • その他の用途
    • リンパ腫
    • 腎細胞がん

第7章 がん免疫療法の世界市場:エンドユーザー別

  • 病院・クリニック
  • 外来手術センター
  • がん研究センター

第8章 がん免疫療法の世界市場:地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東・アフリカ

第9章 主な発展

  • 契約、パートナーシップ、コラボレーション、ジョイントベンチャー
  • 買収と合併
  • 新製品の発売
  • 事業拡大
  • その他の主要戦略

第10章 企業プロファイル

  • Merck & Co., Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Bristol-Myers Squibb
  • ELI Lilly and Company
  • Dr. Reddy's Laboratories Ltd
  • Astrazeneca
  • Amgen Inc.
  • Lupin Limited
  • Bausch Health Companies Inc.
  • Celgene Corporation
  • Apotex Inc
  • Immunomedics Inc
  • Hikma Pharmaceutical PLC
図表

List of Tables

  • Table 1 Global Cancer Immunotherapy Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Cancer Immunotherapy Market Outlook, By Product (2020-2028) ($MN)
  • Table 3 Global Cancer Immunotherapy Market Outlook, By Cytokines & Immunomodulators (2020-2028) ($MN)
  • Table 4 Global Cancer Immunotherapy Market Outlook, By Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf) (2020-2028) ($MN)
  • Table 5 Global Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2020-2028) ($MN)
  • Table 6 Global Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2020-2028) ($MN)
  • Table 7 Global Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2020-2028) ($MN)
  • Table 8 Global Cancer Immunotherapy Market Outlook, By Adoptive Cell Transfer (2020-2028) ($MN)
  • Table 9 Global Cancer Immunotherapy Market Outlook, By Vaccines (2020-2028) ($MN)
  • Table 10 Global Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2020-2028) ($MN)
  • Table 11 Global Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2020-2028) ($MN)
  • Table 12 Global Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2020-2028) ($MN)
  • Table 13 Global Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2020-2028) ($MN)
  • Table 14 Global Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2020-2028) ($MN)
  • Table 15 Global Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2020-2028) ($MN)
  • Table 16 Global Cancer Immunotherapy Market Outlook, By Cell Therapies (2020-2028) ($MN)
  • Table 17 Global Cancer Immunotherapy Market Outlook, By Dendritic Cells (2020-2028) ($MN)
  • Table 18 Global Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2020-2028) ($MN)
  • Table 19 Global Cancer Immunotherapy Market Outlook, By Checkpoint Inhibitors (2020-2028) ($MN)
  • Table 20 Global Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1) (2020-2028) ($MN)
  • Table 21 Global Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2020-2028) ($MN)
  • Table 22 Global Cancer Immunotherapy Market Outlook, By Application (2020-2028) ($MN)
  • Table 23 Global Cancer Immunotherapy Market Outlook, By Blood Cancers (2020-2028) ($MN)
  • Table 24 Global Cancer Immunotherapy Market Outlook, By Ovarian Cancer (2020-2028) ($MN)
  • Table 25 Global Cancer Immunotherapy Market Outlook, By Pancreatic Cancer (2020-2028) ($MN)
  • Table 26 Global Cancer Immunotherapy Market Outlook, By Liver Cancer (2020-2028) ($MN)
  • Table 27 Global Cancer Immunotherapy Market Outlook, By Breast Cancer (2020-2028) ($MN)
  • Table 28 Global Cancer Immunotherapy Market Outlook, By Melanoma (2020-2028) ($MN)
  • Table 29 Global Cancer Immunotherapy Market Outlook, By Lung Cancer (2020-2028) ($MN)
  • Table 30 Global Cancer Immunotherapy Market Outlook, By Gastric Cancer (Stomach Cancer) (2020-2028) ($MN)
  • Table 31 Global Cancer Immunotherapy Market Outlook, By Cervical Cancer (2020-2028) ($MN)
  • Table 32 Global Cancer Immunotherapy Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 33 Global Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2020-2028) ($MN)
  • Table 34 Global Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2020-2028) ($MN)
  • Table 35 Global Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2020-2028) ($MN)
  • Table 36 Global Cancer Immunotherapy Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 37 Global Cancer Immunotherapy Market Outlook, By Lymphoma (2020-2028) ($MN)
  • Table 38 Global Cancer Immunotherapy Market Outlook, By Renal Cell Carcinoma (2020-2028) ($MN)
  • Table 39 Global Cancer Immunotherapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 40 Global Cancer Immunotherapy Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
  • Table 41 Global Cancer Immunotherapy Market Outlook, By Ambulatory Surgical Centres (2020-2028) ($MN)
  • Table 42 Global Cancer Immunotherapy Market Outlook, By Cancer Research Centers (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次
Product Code: SMRC20376

According to Stratistics MRC, the Global Cancer Immunotherapy Market is accounted for $119.39 billion in 2021 and is expected to reach $337.42 billion by 2028 growing at a CAGR of 16.0% during the forecast period. Cancer immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. This therapy is preferable than the old technique because it provides long-term cancer protection, has less side effects, and treats a wider range of cancers.

Market Dynamics:

Driver:

Growing adoption of immunotherapy

The treatment options for cancer, such as chemotherapies and radiation therapy, although have more side effects, are more widely used as compared to immunotherapies. While they can effectively kill or remove cancer cells, the use of these treatments is often limited because they tend to destroy healthy cells in large numbers as well. As immunotherapies involve the mechanism of enhancing the body's own immunity using man-made proteins such as monoclonal antibodies, they are accepted worldwide over other treatment options.

Restraint:

High product developmental cost

The cost of developing new products for cancer immunotherapy is on the higher side. Due to this, there is a negative impact on the growth of the market.

Opportunity:

Technological developments

The developments in technology and surge in healthcare expenditure positively affect the cancer immunotherapy market. Furthermore, increase in clinical trials against several types of cancers in immunotherapy extends profitable opportunities to the market players in the forecast period.

Threat:

Stringent government regulations

The stringent regulations related to cancer immunotherapy are anticipated to be a major threat for the growth of the cancer immunotherapy market. Government have better supervision over the use of immunotherapy and is also taking care of the clinical trials going on user the government norms, which has made it difficult to the companies to enter the industry and is hence expected to hinder the growth of the market.

The hospitals & clinics segment is expected to be the largest during the forecast period

Hospitals and clinics remain the most favoured medical settings, as these institutions are equipped with advanced facilities to allow for effective diagnosis and treatment. High adoption of advanced diagnostics and treatment equipment, as well as therapeutics, supported by public and private funding, further improves the healthcare quality offered by hospitals. Relatively short wait times and ease of getting appointments are projected to widen the patient base opting for clinic-based healthcare. Progressive growth in the demand for quality cancer therapeutics in clinics is influencing clinicians to focus on offering cancer immunotherapy to patients, which is driving the exponential adoption of cancer therapeutics in clinics.

The monoclonal antibodies segment is expected to have the highest CAGR during the forecast period

Monoclonal antibody based drugs assist in flagging cancer cells, trigger cell-membrane destruction, inhibiting malignant cell proliferation, preventing blood vessel growth, easy chemotherapy delivery and binding cancer and immune cells among other benefits. Their ability to trigger an antitumor immune response makes them highly sought after.

Region with largest share:

North America is projected to hold the largest market share owing to the favourable dynamics, such as progressive improvements in healthcare infrastructure and government initiatives underpinning the R&D activities of players. The rising number of patients suffering from cancer, increasing adoption rate of immunotherapy, and development of bioinformatics tools are enhancing the drug development process also contribute towards the market growth.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the increasing ageing population, altering lifestyles and socio-economic changes. Consequently, healthcare spending to develop advanced research & development facilities for designing high-grade oncology diagnostics are taking place, a factor which is expected to fuel cancer immunotherapy market growth.

Key players in the market

Some of the key players profiled in the Cancer Immunotherapy Market include Merck & Co., Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Bristol-Myers Squibb, ELI Lilly and Company, Dr. Reddy's Laboratories Ltd, Astrazeneca, Amgen Inc., Lupin Limited, Bausch Health Companies Inc., Celgene Corporation, Apotex Inc, Immunomedics Inc, and Hikma Pharmaceutical PLC.

Key developments:

In September 2021: Amgen Plc. announced its first combination study results from its Phase 1b/2 CodeBreaK 101 study, a comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer. It shows that combining LUMAKRASTM (sotorasib) with Vectibix® (panitumumab) demonstrate efficacy and safety.

In September 2021: Bristol-Myers Squibb Company conducted a survey that included 250 oncologists, surgeons and specialists from countries like U.S., Germany and Japan. The survey revealed the potential immunotherapy carries for cancers that are detected at an early stage.

Products Covered:

  • Cytokines & Immunomodulators
  • Adoptive Cell Transfer
  • Vaccines
  • Monoclonal Antibodies
  • Cell Therapies
  • Checkpoint Inhibitors

Applications Covered:

  • Blood Cancers
  • Ovarian Cancer
  • Pancreatic Cancer
  • Liver Cancer
  • Breast Cancer
  • Melanoma
  • Lung Cancer
  • Gastric Cancer (Stomach Cancer)
  • Cervical Cancer
  • Prostate Cancer
  • Multiple Myeloma
  • Head & Neck Cancer
  • Colorectal Cancer
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Ambulatory Surgical Centres
  • Cancer Research Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Immunotherapy Market, By Product

  • 5.1 Introduction
  • 5.2 Cytokines & Immunomodulators
    • 5.2.1 Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf)
    • 5.2.2 Interleukins (IL)
    • 5.2.3 Interferons (IFN)
    • 5.2.4 Oncolytic Virus
      • 5.2.4.1 Immunity as an Ally
      • 5.2.4.2 Immunity as an Obstacle
      • 5.2.4.3 Approved Products & Clinical Trails
      • 5.2.4.4 Immunotherapy/Non-Specific Immunotherapies
  • 5.3 Adoptive Cell Transfer
  • 5.4 Vaccines
    • 5.4.1 Therapeutic Vaccines
    • 5.4.2 Prophylactic Vaccines
  • 5.5 Monoclonal Antibodies
    • 5.5.1 Conjugated Monoclonal Antibodies
    • 5.5.2 Naked Monoclonal Antibodies
    • 5.5.3 Bispecific Monoclonal Antibodies
  • 5.6 Cell Therapies
    • 5.6.1 Dendritic Cells
    • 5.6.2 Chimeric Antigen Receptor (CAR) T Cell Therapy
  • 5.7 Checkpoint Inhibitors
    • 5.7.1 Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
    • 5.7.2 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)

6 Global Cancer Immunotherapy Market, By Application

  • 6.1 Introduction
  • 6.2 Blood Cancers
  • 6.3 Ovarian Cancer
  • 6.4 Pancreatic Cancer
  • 6.5 Liver Cancer
  • 6.6 Breast Cancer
  • 6.7 Melanoma
  • 6.8 Lung Cancer
  • 6.9 Gastric Cancer (Stomach Cancer)
  • 6.10 Cervical Cancer
  • 6.11 Prostate Cancer
  • 6.12 Multiple Myeloma
  • 6.13 Head & Neck Cancer
  • 6.14 Colorectal Cancer
  • 6.15 Other Applications
    • 6.15.1 Lymphoma
    • 6.15.2 Renal Cell Carcinoma

7 Global Cancer Immunotherapy Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals & Clinics
  • 7.3 Ambulatory Surgical Centres
  • 7.4 Cancer Research Centers

8 Global Cancer Immunotherapy Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Merck & Co., Inc.
  • 10.2 Bayer AG
  • 10.3 F. Hoffmann-La Roche Ltd
  • 10.4 GlaxoSmithKline Plc
  • 10.5 Bristol-Myers Squibb
  • 10.6 ELI Lilly and Company
  • 10.7 Dr. Reddy's Laboratories Ltd
  • 10.8 Astrazeneca
  • 10.9 Amgen Inc.
  • 10.10 Lupin Limited
  • 10.11 Bausch Health Companies Inc.
  • 10.12 Celgene Corporation
  • 10.13 Apotex Inc
  • 10.14 Immunomedics Inc
  • 10.15 Hikma Pharmaceutical PLC